Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 56 of 5804
-
New combo therapy targets Brain-Attacking antibodies in severe encephalitis
Disease control Recruiting nowAutoimmune encephalitis is an autoimmune disease of the central nervous system that targets neuronal autoantigens. Anti-neuronal autoantibodies are produced in patients, with anti-NMDAR antibody being the most common.Anti-NMDAR encephalitis can be severe and life-threatening. Ant…
Phase: PHASE3 • Sponsor: The First People's Hospital of Changzhou • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Could a daily powder cure food allergies in kids?
⭐️ CURE ⭐️ Recruiting nowThe aim is to study whether a multiallergen oral immunotherapy (OIT) strategy with slow up-dosing and low treatment dose against food allergy in young children (0.5-3 years) is safe and effective, a method to cure food allergy and to prevent the development of new food allergies.…
Phase: NA • Sponsor: Karolinska Institutet • Aim: ⭐️ CURE ⭐️
Last updated Jun 26, 2026 18:28 UTC
-
Sound waves could boost brain cancer drug delivery
Disease control Recruiting nowThis will be a prospective, randomized, standard of care (SoC) controlled, parallel, open-label, multicenter pivotal study to investigate the efficacy and safety of Bevacizumab (BEV) in combination with or without microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV …
Phase: PHASE3 • Sponsor: NaviFUS Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
One-Shot gene therapy could free hemophilia b patients from frequent injections
Disease control Recruiting nowThe aim of the study is to demonstrate non-inferiority of ANB-002 compared with preventive use of coagulation factor IX (FIX) in adult subjects with hemophilia B with FIX activity ≤2% and without FIX inhibitor. The study will have an open-label single-arm design.
Phase: PHASE3 • Sponsor: Biocad • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Precision radiation may cure prostate cancer with fewer side effects
⭐️ CURE ⭐️ Recruiting nowThe purpose of this prostate cancer research study is to investigate: 1. For early-stage patients, the use of a single session of high dose stereotactic body radiotherapy (SBRT) delivered to the tumor within the prostate, not to the entire prostate, as curative treatment of pros…
Phase: PHASE2 • Sponsor: University of Miami • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 09:06 UTC
-
CRISPR therapy shows promise in early trial for fatal muscle disease
Disease control CompletedDuchenne muscular dystrophin (DMD) is an X-linked, fatal muscle-wasting disease caused by mutations in the DMD gene encoding the dystrophin proteins, with symptom onset before age of 6 years in boys. These mutations abolish dystrophin production in the muscle, leading to dystroph…
Phase: EARLY_PHASE1 • Sponsor: HuidaGene Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Can whole blood save more kids? major trial launches
Disease control Recruiting nowThe MATIC-2 is a multicenter clinical trial enrolling children who are less than 18 years of age with hemorrhagic shock potentially needing significant blood transfusion. The primary objective of the clinical trial is to determine the effectiveness of Low Titer Group O Whole Blo…
Phase: PHASE3 • Sponsor: Philip Spinella • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Triple attack: radiation, immunotherapy, and chemo take on tough breast cancer
Disease control Recruiting nowTriple-negative breast cancer (TNBC) presents significant challenges due to its limited treatment options and poor efficacy. While neoadjuvant chemotherapy has improved breast-conserving rates and extended survival for TNBC patients, this subtype still faces issues such as restri…
Phase: PHASE3 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New obesity drug retatrutide takes on tirzepatide in major trial
Disease control OngoingThe main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New hope for lung cancer patients who can't use standard immunotherapy alone
Disease control OngoingThe study aims to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab versus chemotherapy in combination with pembrolizumab in the first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC with PD-L1 negative.
Phase: PHASE3 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
One-Time cell therapy aims to tame tough scleroderma
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Triple threat: new combo aims to outsmart advanced liver cancer
Disease control Recruiting nowTHis study aims to evaluate the efficacy of SHR-8068 combined with Adebrelimab and Bevacizumab compared with Sintilimab or Atezolizumab combined with Bevacizumab for the first-line treatment of advanced HCC.
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Could this drug stop the body from turning muscle into bone?
Disease control OngoingThis study is researching an experimental drug called andecaliximab. The study will include pediatric and adult patients with fibrodysplasia ossificans progressiva (FOP). The study will evaluate how safe and effective andecaliximab is in patients with FOP. The study is looking a…
Phase: PHASE2, PHASE3 • Sponsor: Ashibio Inc • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Could this injection delay Alzheimer's decline?
Disease control OngoingThe purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including sc…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New pneumonia vaccine trial aims to shield 3,000 kids from deadly infection
⭐️ VACCINE ⭐️ Recruiting nowA Phase Ⅲ clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 6 weeks)-5 years (before 6th birthday). The objective of the study is to evaluate the immunogen…
Phase: PHASE3 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:00 UTC
-
Postpartum blood pressure control may stop preeclampsia from leading to lifelong hypertension
Prevention Recruiting nowThe long-term goal of our work is to evaluate the effect of intensive postpartum blood pressure control on maternal cardiovascular health, risk of chronic hypertension, and reversal of vascular dysfunction generated by hypertensive disorders of pregnancy, thus attenuating the lif…
Phase: NA • Sponsor: Medical College of Wisconsin • Aim: Prevention
Last updated Jul 22, 2026 00:00 UTC
-
Groundbreaking gene therapy aims to fix immune system in rare disease
Disease control ENROLLING_BY_INVITATIONThis is an open-label, single-arm, multicenter Phase 1/2 study evaluating the safety and efficacy of gene therapy by transplantation of Prime Edited autologous CD34+ stem cells modified ex vivo (PM359) in participants with autosomal recessive Chronic Granulomatous Disease (CGD) c…
Phase: PHASE1, PHASE2 • Sponsor: Prime Medicine, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Immunotherapy shows promise for untreated rectal cancer in chinese patients
Disease control OngoingThe main goal of this study is to evaluate the effect of dostarlimab monotherapy in Chinese participants with locally advanced Mismatch-repair deficient (dMMR)/ Microsatellite instability-high (MSI-H) rectal cancer who have received no prior treatment.
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Engineered immune cells take on lupus in early trial
Disease control Recruiting nowThe goal of this study is to evaluate the safety and efficacy of CD19 CAR T cells in the treatment of Systemic lupus erythematosus (SLE).
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New catheter aims to treat dangerous blood clots in the lungs without ICU stay
Disease control Recruiting nowTo demonstrate the efficacy and safety of the 8F BASHIR™ .035 Endovascular Catheter and the 8F BASHIR™ S-B .035 Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using pulse sprays of r-tPA into the pulmonary arteries for the treatment …
Phase: NA • Sponsor: Thrombolex, Inc. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC